PET-RM MULTITRAZADOR EN EL ESTUDIO DE LA ENFERMEDAD DE ALZHEIMER
Palabras clave:
ALZHEIMER, enfermedad, precoz, detección, metabolismoResumen
Describir la utilidad de los biomarcadores PET tanto de metabolismo neuronal (PET-FDG) como de depósito de proteína de beta amiloide (PET-Amiloide) en la detección precoz, control y monitorización del paciente con enfermedad de Alzheimer (EA). Explicar la importancia de la imagen PET-RM en la mejora del diagnóstico en aquellas situaciones donde la PET muestre limitaciones
Descargas
Citas
-Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers. Xu L, Wu X, Li R, Chen K, Long Z, Zhang J, Guo X, Yao L; Alzheimer’s Disease Neuroimaging Initiative.
J Alzheimers Dis. 2016 Feb 25
-Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.
Laforce R, Rosa-Neto P, Soucy JP, Rabinovici GD, Dubois B, Gauthier S.
Can J Neurol Sci. 2016 Feb 26:1-10
-Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-PiB PET for Assessing Brain Perfusion in Alzheimer's Disease.
Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Schöll M, Almkvist O, Wall A, Långström B, Nordberg A.
J Nucl Med. 2016 Feb 16
-Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.
Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, Oh J, Verma A, Sampat M, Barakos J. Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7
-Brain fluorodeoxyglucose (FDG) PET in dementia.
Kato T, Inui Y, Nakamura A, Ito K.
Ageing Res Rev. 2016 Feb 11. pii: S1568-1637(16)30011-3. doi: 10.1016/j.arr.2016.02.003.
-Fusion FDG-PET/MRI Evidence to Support Diagnosis of Frontotemporal Dementia-Related Primary Progressive Aphasia.
VanDreel A, Aftab SA, Sanan P, Grant C, Lu Y.
Clin Nucl Med. 2016 Feb 6
-Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: A study combining MRI and FDG-PET.
Buhour MS, Doidy F, Laisney M, Pitel AL, de La Sayette V, Viader F, Eustache F, Desgranges B. Brain Imaging Behav. 2016 Feb 6
-Brain Metabolism Correlates of The Free and Cued Selective Reminding Test in Mild Cognitive Impairment.
Caffarra P, Ghetti C, Ruffini L, Spallazzi M, Spotti A, Barocco F, Guzzo C, Marchi M, Gardini S. J Alzheimers Dis. 2016 Jan 13;51(1):27-31.
-Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a Phase 3 trial.
Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Takao M, Akatsu H, Murayama S, Bullich S, Mueller A, Koglin N, Schulz-Schaeffer WJ, Hoffmann A, Sabbagh M, Stephens AW, Sabri O.J Nucl Med. 2016 Jan 28.
-Amyloid imaging using fluorine-19 magnetic resonance imaging (19F-MRI).
Tooyama I, Yanagisawa D, Taguchi H, Kato T, Hirao K, Shirai N, Sogabe T, Ibrahim NF, Inubushi T, Morikawa S.
Ageing Res Rev. 2016 Jan 6. pii: S1568-1637(15)30044-1.
-Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.
Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative.
Alzheimers Res Ther. 2016 Jan 15;8(1):2.
-Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ; 18F-AV-45-A17 Study Group.
Dement Geriatr Cogn Disord. 2016;41(1-2):80-92
-Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45/Amyvid) PET study.
Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, Hsieh CJ, Lee CP, Yen TC, Lin KJ.
Eur J Nucl Med Mol Imaging. 2016 Jan 7
-Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease.
Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz HJ, Hesse S, Seese A, Lobsien D, Sabri O, Barthel H.
Eur J Nucl Med Mol Imaging. 2016 Jan 7
-The Compression Flow as a Measure to Estimate the Brain Connectivity Changes in Resting State fMRI and 18FDG-PET Alzheimer's Disease Connectomes.
Zippo AG, Castiglioni I, Borsa VM, Biella GE.
Front Comput Neurosci. 2015 Dec 16;9:148
-Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging.
Shimojo M, Higuchi M, Suhara T, Sahara N.
Front Neurosci. 2015 Dec 22;9:482
-Metabolic connectivity for differential diagnosis of dementing disorders.
Titov D, Diehl-Schmid J, Shi K, Perneczky R, Zou N, Grimmer T, Li J, Drzezga A, Yakushev I. J Cereb Blood Flow Metab. 2015 Dec 31
-Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. Eisenmenger LB, Huo EJ, Hoffman JM, Minoshima S, Matesan MC, Lewis DH, Lopresti BJ, Mathis CA, Okonkwo DO, Mountz JM.
Semin Nucl Med. 2016 Jan;46(1):57-87
-Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.
Adamczuk K, Schaeverbeke J, Vanderstichele HM, Lilja J, Nelissen N, Van Laere K, Dupont P, Hilven K, Poesen K, Vandenberghe R.
Alzheimers Res Ther. 2015 Dec 18;7(1):75
-Early detection of Alzheimer's disease using MRI hippocampal texture.
Sørensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, Nielsen M; Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. Hum Brain Mapp. 2016 Mar;37(3):1148-61
-ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia.
Frey KA, Lodge MA, Meltzer CC, Peller PJ, Wong TZ, Hess CP, Petrella JR, Sair HI, Subramaniam RM.
Clin Nucl Med. 2016 Feb;41(2):118-25
-Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis. Mishima A, Nihashi T, Ando Y, Kawai H, Kato T, Ito K, Terasawa T.
J Alzheimers Dis. 2015 Nov 30;50(1):161-74
-Cerebral Glucose Metabolism Assessment in Rat Models of Alzheimer's Disease: An 18F-FDG-PET Study.
Lu Y, Ren J, Cui S, Chen J, Huang Y, Tang C, Shan B, Nie B, Xinsheng L.
Am J Alzheimers Dis Other Demen. 2015 Dec
-Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S.
Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):374-85
-Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.
Jack CR Jr, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Mielke MM, Vemuri P, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC.
Lancet Neurol. 2016 Jan;15(1):56-64
-Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS, Machulda MM, Geda YE, Jack CR Jr.
JAMA Neurol. 2016 Jan 1;73(1):85-92
- Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A. J Nucl Med. 2016 Feb;57(2):204-7
-Tau imaging in neurodegenerative diseases. Dani M, Brooks DJ, Edison P.
Eur J Nucl Med Mol Imaging. 2015 Nov 16
